Sonoma Pharmaceuticals Updates Investor Presentation on HOCl Portfolio

Sonoma Pharmaceuticals ( (SNOA) ) has shared an update.

In January 2026, Sonoma Pharmaceuticals released an updated investor presentation highlighting its leadership in hypochlorous acid technology and the breadth of its Microcyn product portfolio across billion‑dollar markets such as prescription and over‑the‑counter dermatology, wound care, eye care, podiatry, animal health and non‑toxic disinfectants. The company detailed its strong safety and efficacy profile, extensive clinical and research backing, diversified global distribution footprint and cost‑efficient manufacturing, while also underscoring recent commercial momentum, including the addition of Medline Industries as a U.S. wound care distributor in August 2024, expansion of that partnership to Canada and OTC channels in October 2024, new wound care distribution in Ukraine, and ongoing product innovation such as expanded negative pressure wound therapy solutions and an intraoperative pulse lavage irrigation application announced in June 2023, developments that collectively aim to accelerate international growth and deepen market penetration for its HOCl‑based technologies.

The most recent analyst rating on (SNOA) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Sonoma Pharmaceuticals stock, see the SNOA Stock Forecast page.

Spark’s Take on SNOA Stock

According to Spark, TipRanks’ AI Analyst, SNOA is a Neutral.

Sonoma Pharmaceuticals faces significant financial challenges, with ongoing losses and liquidity issues. However, strategic growth initiatives and partnerships in the healthcare sector provide a positive outlook. Technical indicators suggest balanced market sentiment, but valuation concerns persist due to negative earnings.

To see Spark’s full report on SNOA stock, click here.

More about Sonoma Pharmaceuticals

Sonoma Pharmaceuticals is a global healthcare company specializing in the development and production of stabilized hypochlorous acid (HOCl) products used across wound care, eye care, dermatology, podiatry, animal health and non‑toxic disinfectants, with clinically proven solutions that reduce itch, pain, scarring and irritation without damaging healthy tissue. Leveraging its proprietary Microcyn technology, extensive regulatory clearances including 22 U.S. FDA 510(k) medical device approvals, a 20‑year track record, and manufacturing facilities in Mexico, Sonoma sells directly and through a broad partner network in more than 55 countries, positioning itself as an industry leader in HOCl‑based medical and consumer products.

Average Trading Volume: 30,741

Technical Sentiment Signal: Hold

Current Market Cap: $6.43M

See more insights into SNOA stock on TipRanks’ Stock Analysis page.